Androgen Receptor in Prostate Cancer

Endocrine Reviews - Tập 25 Số 2 - Trang 276-308 - 2004
Cynthia Heinlein1, Chawnshang Chang1
1George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester, Rochester, New York 14642

Tóm tắt

Từ khóa


Tài liệu tham khảo

Roy, 1999, Regulation of androgen action., Vit Horm, 55, 309, 10.1016/S0083-6729(08)60938-3

Heinlein, 2002, Androgen receptor (AR) coregulators: an overview., Endocr Rev, 23, 175, 10.1210/edrv.23.2.0460

Buchanan, 2001, Contribution of the androgen receptor to prostate cancer predisposition and progression., Cancer Metastasis Rev, 20, 207, 10.1023/A:1015531326689

Cunha, 1987, The endocrinology and developmental biology of the prostate., Endocr Rev, 8, 338, 10.1210/edrv-8-3-338

Denis, 2000, Endocrine treatment in prostate cancer., Sem Surg Oncol, 18, 52, 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6

Mohler, 1996, Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma., Clin Cancer Res, 2, 889

Kwast, 1991, Androgen receptors in endocrine-therapy-resistant human prostate cancer., Int J Cancer, 48, 189, 10.1002/ijc.2910480206

Sadi, 1991, Immunohistochemical study of androgen receptors in metastatic prostate cancer., Cancer, 67, 3057, 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S

Chodak, 1992, Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate., J Urol, 147, 798, 10.1016/S0022-5347(17)37389-5

Hobisch, 1996, Androgen receptor status of lymph node metastases from prostate cancer., Prostate, 28, 129, 10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B

Shapiro, 2000, 1

Siiteri, 1974, Testosoterone formation and metabolism during male sexual differentiation in the human embryo., J Clin Endocrinol Metab, 38, 113, 10.1210/jcem-38-1-113

Imperato-McGinley, 1985, The development of a male pseudohermaphroditic rat using an inhibitor of the enzyme 5 α-reductase., Endocrinology, 116, 807, 10.1210/endo-116-2-807

Wilson, 1993, Steroid 5 α-reductase 2 deficiency., Endocr Rev, 14, 577

Yeh, 2002, Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues., Proc Natl Acad Sci USA, 99, 13498, 10.1073/pnas.212474399

Quigley, 1995, Androgen receptor defects: historical, clinical, and molecular perspectives., Endocr Rev, 16, 271

Lyon, 1970, X-linked gene for testicular feminization in the mouse., Nature, 227, 1217, 10.1038/2271217a0

Lasnitzki, 1980, Prostatic induction: interaction of epithelium and mesenchyme from normal wild-type mice and androgen-insensitive mice with testicular feminization., J Endocrinol, 85, 423, 10.1677/joe.0.0850423

Cunha, 1978, The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild type and androgen insensitive (Tfm) mice., J Exp Zool, 205, 181, 10.1002/jez.1402050203

Donjacour, 1993, Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen insensitive mice., Endocrinology, 132, 2342, 10.1210/endo.132.6.7684975

Cooke, 1991, Androgen receptor expression in developing male reproductive organs., Endocrinology, 128, 2867, 10.1210/endo-128-6-2867

Prins, 1995, The developmental pattern of androgen expression in rat prostate lobes is altered after neonatal exposure to estrogen., Endocrinology, 136, 1303, 10.1210/endo.136.3.7867585

Liao, Proc Natl Acad Sci USA, 82, 8345, 10.1073/pnas.82.24.8345

Chang, Science, 240, 324, 10.1126/science.3353726

Lubahn, 1998, Cloning of human androgen receptor complementary DNA and localization to the X chromosome., Science, 240, 327, 10.1126/science.3353727

Marzo, 1998, Stem cell features of benign and malignant prostate epithelial cells., J Urol, 160, 2381, 10.1016/S0022-5347(01)62196-7

Berges, 1995, Implication of cell kinetic changes during the progression of human prostate cancer., Clin Cancer Res, 1, 473

Isaacs, 1984, Antagonistic effect of androgen on prostatic cell death., Prostate, 5, 545, 10.1002/pros.2990050510

English, 1989, Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration., Prostate, 15, 233, 10.1002/pros.2990150304

Prins, 1991, Androgen receptor localization in different cell types of the adult rat prostate., Endocrinology, 129, 3187, 10.1210/endo-129-6-3187

Prins, 1993, Immunocytochemical analysis of androgen receptor along the ducts of the separate rat prostate lobes after androgen withdrawal and replacement., Endocrinology, 132, 169, 10.1210/endo.132.1.8419121

Wright, 1996, Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat., J Clin Invest, 98, 2558, 10.1172/JCI119074

Jin, 1996, Androgen or estrogen effects on human prostate., J Clin Endocrinol Metab, 81, 4290

Berry, 1984, Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat., Endocrinology, 114, 511, 10.1210/endo-114-2-511

Pentyala, 2000, Prostate cancer: a comprehensive review., Med Oncol, 17, 85, 10.1007/BF02796203

Roberts, 1986, Adenocarcinoma of prostate in 40 year old body-builder., Lancet, 2, 742, 10.1016/S0140-6736(86)90251-5

Hsing, 2001, Hormones and prostate cancer: what’s next?, Epidemiol Rev, 23, 42, 10.1093/oxfordjournals.epirev.a000795

Buttyan, 1999, Regulation of apoptosis in the prostate gland by androgenic steroids., Trends Endocrinol Metab, 10, 47, 10.1016/S1043-2760(98)00104-0

Buttyan, 2000, The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression., Curr Opin Urol, 10, 415, 10.1097/00042307-200009000-00009

Franck-Lissbrant, 1998, Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats., Endocrinology, 139, 451, 10.1210/endo.139.2.5683

Russell, 1998, Growth factor involvement in progression of prostate cancer., Clin Chem, 44, 705, 10.1093/clinchem/44.4.705

Katz, 1989, Gene activity during the early phase of androgen stimulated rat prostate regrowth., Cancer Res, 49, 5889

Burchardt, 2000, Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration., Prostate, 43, 184, 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO;2-6

Haggstrom, 1998, Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration., Prostate, 36, 71, 10.1002/(SICI)1097-0045(19980701)36:2<71::AID-PROS1>3.0.CO;2-H

Schatzl, 2002, Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men., Prostate, 52, 130, 10.1002/pros.10101

Lee, 2003, High androgen receptor levels are predictive of decreased survival in prostate cancer., Clin Prostate Cancer, 2, 13, 10.1016/S1540-0352(11)70012-9

Fowler, 1982, Considerations for the use of testosterone with systemic chemotherapy in prostate cancer., Cancer, 49, 1373, 10.1002/1097-0142(19820401)49:7<1373::AID-CNCR2820490712>3.0.CO;2-G

Dawson, 2000, 378

Winter, 1994, Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer., Am J Pathol, 144, 735

Lee, J Clin Endocrinol Metab, 88, 4043, 10.1210/jc.2003-030261

Takeda, 1996, Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma., Cancer, 77, 934, 10.1002/(SICI)1097-0142(19960301)77:5<934::AID-CNCR20>3.0.CO;2-3

Stanbrough, 2001, Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium., Proc Natl Acad Sci USA, 98, 10823, 10.1073/pnas.191235898

Kim, 2002, Androgen receptor expression and cellular proliferation during transition from androgen dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft., Am J Pathol, 160, 219, 10.1016/S0002-9440(10)64365-9

Alers, 2000, Identification of genetic markers for prostatic cancer progression., Lab Invest, 80, 931, 10.1038/labinvest.3780096

Cunningham, 1996, Allelic imbalance and microsatellite instability in prostatic adenocarcinoma., Cancer Res, 56, 4475

Nupponen, 1998, Genetic alterations in hormone refractory recurrent prostate carcinomas., Am J Pathol, 153, 141, 10.1016/S0002-9440(10)65554-X

Sasaki, 2002, Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer., J Natl Cancer Inst, 94, 384, 10.1093/jnci/94.5.384

Lin, 2002, Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase., EMBO J, 21, 4037, 10.1093/emboj/cdf406

Labrie, 1993, Mechanism of action and pure antiandrogenic properties of flutamide., Cancer, 72, 3816, 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3

Labrie, 1988, Benefits of combination therapy with flutamide in patients relapsing after castration., Br J Urol, 61, 341, 10.1111/j.1464-410X.1988.tb13971.x

Forti, 1989, Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 α-reductase activity and androgen receptor content., J Clin Endocrinol Metab, 68, 461, 10.1210/jcem-68-2-461

Nishiyama, 2002, Changes in dihydrotestosterone level in prostatic tissues before and after hormonal therapy for prostate cancer, J Urol, 167, 46

2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials., Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2

Reuter, 1997, Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy, Urology, 49, 16, 10.1016/S0090-4295(97)00164-7

Armas, 1994, Clinical and pathobiological effects of neoadjuvant total androgen ablation on clinically localized prostatic carcinoma., Am J Surg Pathol, 18, 979, 10.1097/00000478-199410000-00002

Murphy, 1991, Pathologic changes associated with androgen deprivation therapy for prostate cancer., Cancer, 68, 821, 10.1002/1097-0142(19910815)68:4<821::AID-CNCR2820680426>3.0.CO;2-S

Westin, 1995, Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors., Am J Pathol, 146, 1368

Matsushima, 1999, Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation., Cancer, 85, 1822, 10.1002/(SICI)1097-0142(19990415)85:8<1822::AID-CNCR24>3.0.CO;2-1

Brandstrom, 1994, Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat., Cancer Res, 54, 3594

Westin, 1993, Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma., Prostate, 22, 65, 10.1002/pros.2990220109

Colombel, 1993, Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers., Am J Pathol, 143, 390

Krajewska, 1996, Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers., Am J Pathol, 148, 1567

Raffo, 1995, Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo., Cancer Res, 55, 4438

Bruckheimer, 2003, Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells., J Urol, 169, 1553, 10.1097/01.ju.0000055140.91204.c7

Rosini, 2002, Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down modulation., Prostate, 53, 310, 10.1002/pros.10164

Prehn, 1999, On the prevention and therapy of prostate cancer by androgen administration., Cancer Res, 59, 4161

Sonnenschein, 1989, Negative controls of cell proliferation: human prostate cancer cells and androgens., Cancer Res, 49, 3474

Joly-Pharaboz, 2000, Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line., J Steroid Biochem Mol Biol, 73, 237, 10.1016/S0960-0760(00)00076-5

Umekita, 1996, Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride., Proc Natl Acad Sci USA, 93, 11802, 10.1073/pnas.93.21.11802

Geck, 1997, Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells., J Steroid Biochem Mol Biol, 63, 211, 10.1016/S0960-0760(97)00122-2

Heisler, 1997, Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor., Mol Cell Endocrinol, 126, 59, 10.1016/S0303-7207(96)03970-6

Yuan, 1993, Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA., Cancer Res, 53, 1304

Wolff, 2000, Intermittent androgen blockade in prostate cancer: rationale and clinical experience., Eur Urol, 38, 365, 10.1159/000020310

Dawson, 2000, Intermittent androgen deprivation., Curr Oncol Rep, 2, 409, 10.1007/s11912-000-0060-6

Zhang, Cancer Res, 63, 4552

Sato, 1996, Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model., J Steroid Biochem Mol Biol, 58, 139, 10.1016/0960-0760(96)00018-0

Reigman, 1989, Characterization of the prostate specific antigen gene: a novel kallikrein-like gene., Biochem Biophys Res Commun, 159, 95, 10.1016/0006-291X(89)92409-1

Lilja, 1985, A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein., J Clin Invest, 76, 1899, 10.1172/JCI112185

Stenman, 1997, Prostate-specific antigen, clinical use and staging: an overview, Br J Urol, 79, 53, 10.1111/j.1464-410X.1997.tb00802.x

Stenman, 1999, Prostate-specific antigen., Semin Cancer Biol, 9, 83, 10.1006/scbi.1998.0086

Lopez-Otin, 1998, Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features., Endocr Rev, 19, 365, 10.1210/er.19.4.365

Cleutjens, 1997, An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter., Mol Endocrinol, 11, 148, 10.1210/mend.11.2.9883

Cleutjens, 1996, Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter., J Biol Chem, 271, 6379, 10.1074/jbc.271.11.6379

Kollara, 2003, Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells., J Ster Biochem Mol Biol, 84, 493, 10.1016/S0960-0760(03)00069-4

Yu, 1994, Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cell lines., Breast Cancer Res Treat, 32, 291, 10.1007/BF00666006

Cluetjens, 1997, Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth stimulating properties of LNCaP cells., Endocrinology, 138, 5293, 10.1210/endo.138.12.5564

Zarghami, 1997, Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer., Br J Cancer, 75, 579, 10.1038/bjc.1997.101

Yu, 1995, Oral contraceptive-induced expression of prostate-specific antigen in the female breast., J Biol Chem, 270, 6615, 10.1074/jbc.270.12.6615

Wang, 2003, Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen., J Biol Chem, 278, 32423, 10.1074/jbc.M207862200

Oettgen, 1999, Characterization of ESE-2, a novel ESE-1 related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes., J Biol Chem, 274, 29439, 10.1074/jbc.274.41.29439

Oettgen, 2000, PDEF, a novel prostate-epithelium specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression., J Biol Chem, 275, 1216, 10.1074/jbc.275.2.1216

Lubahn, 1988, The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in the prostate., Mol Endocrinol, 2, 1265, 10.1210/mend-2-12-1265

Chang, 1988, Structural analysis of complementary DNA and amino acid sequences of the human and rat androgen receptors., Proc Natl Acad Sci USA, 85, 7211, 10.1073/pnas.85.19.7211

Jenster, 1991, Domains of the androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization., Mol Endocrinol, 5, 1396, 10.1210/mend-5-10-1396

Simental, 1991, Transcriptional activation and nuclear targeting signals of the human androgen receptor., J Biol Chem, 266, 510, 10.1016/S0021-9258(18)52466-2

Gill, 1994, A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation., Proc Natl Acad Sci USA, 91, 192, 10.1073/pnas.91.1.192

Hoey, 1993, Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators., Cell, 72, 247, 10.1016/0092-8674(93)90664-C

Nakajima, 1997, Analysis of a cAMP responsive activator reveals a two component mechanism for transcriptional induction via signal-dependent factors., Genes Dev, 11, 738, 10.1101/gad.11.6.738

Gao, 1996, Transcriptional activation and transient expression of the human androgen receptor., J Steroid Biochem Mol Biol, 59, 9, 10.1016/S0960-0760(96)00097-0

Chamberlain, 1994, The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function., Nucl Acids Res, 22, 3181, 10.1093/nar/22.15.3181

Kazemi-Esfarjani, 1995, Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies., Hum Mol Genet, 4, 523, 10.1093/hmg/4.4.523

Zitzmann, 2003, Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study., J Clin Endocrinol Metab, 88, 2049, 10.1210/jc.2002-021947

Choong, 1998, Trinucleotide repeats in the human androgen receptor: a molecular basis for disease., J Mol Endocrinol, 21, 235, 10.1677/jme.0.0210235

Coetzee, 1994, Re: Prostate cancer and the androgen receptor., J Natl Cancer Inst, 86, 872, 10.1093/jnci/86.11.872

Cerhan, 1999, Family history and prostate cancer risk in a population-based cohort of Iowa men., Cancer Epidemiol Biomarkers Prev, 8, 53

Lesko, 1996, Family history and prostate cancer risk., Am J Epidemiol, 144, 1041, 10.1093/oxfordjournals.aje.a008876

Stanford, 2001, Familial prostate cancer., Epidemiol Rev, 23, 19, 10.1093/oxfordjournals.epirev.a000789

Xu, 2001, Linkage and association of prostate cancer susceptibility: evidence for linkage at 8p22–23., Am J Hum Genet, 69, 341, 10.1086/321967

Lange, 1999, Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX., Clin Cancer Res, 5, 4013

Tavtigian, 2001, A candidate prostate cancer susceptibility gene at chromosome 17p., Nat Genet, 27, 172, 10.1038/84808

Goddard, 2001, Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4., Am J Hum Genet, 68, 1197, 10.1086/320103

Nwosu, 2001, Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease., Hum Mol Genet, 10, 2313, 10.1093/hmg/10.20.2313

Edwards, 1992, Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups., Genomics, 12, 241, 10.1016/0888-7543(92)90371-X

Hsing, 2000, Polymorphic CAG and GGN repeat lengths in the androgen receptor and prostate cancer risk: a population-based case control study in China., Cancer Res, 60, 5111

Irvine, 1995, The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer., Cancer Res, 55, 1937

La Spada, 1991, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy., Nature, 352, 77, 10.1038/352077a0

Beilin, 2000, Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines., J Mol Endocrinol, 25, 85, 10.1677/jme.0.0250085

Irvine, 2000, Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length., Hum Mol Genet, 9, 267, 10.1093/hmg/9.2.267

Xue, 2001, Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort., Cancer Epidemiol Biomarkers Prev, 10, 575

Hakimi, 1997, Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer., Clin Cancer Res, 3, 1599

Ingles, 1997, Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor., J Natl Cancer Inst, 89, 166, 10.1093/jnci/89.2.166

Bratt, 1999, CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not prostate cancer risk., Br J Cancer, 81, 672, 10.1038/sj.bjc.6690746

Beilin, 2001, A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects., Cancer, 92, 941, 10.1002/1097-0142(20010815)92:4<941::AID-CNCR1404>3.0.CO;2-P

Hardy, 1996, Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset., J Clin Endocrinol Metab, 81, 4400

Giovannucci, 1997, The CAG repeat within the androgen receptor gene and its relationship to prostate cancer., Proc Natl Acad Sci USA, 94, 3320, 10.1073/pnas.94.7.3320

Stanford, 1997, Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk., Cancer Res, 57, 1194

Correa-Cerro, 1999, (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population., Eur J Hum Genet, 7, 357, 10.1038/sj.ejhg.5200298

Miller, 2001, Polymorphic repeats in the androgen receptor gene in high risk sibships., Prostate, 48, 200, 10.1002/pros.1098

Edwards, 1999, Androgen receptor polymorphisms: association with prostate cancer risk, relapse, and overall survival., Int J Cancer, 84, 458, 10.1002/(SICI)1097-0215(19991022)84:5<458::AID-IJC2>3.0.CO;2-Y

Jin, 2000, Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men., J Androl, 21, 91, 10.1002/j.1939-4640.2000.tb03280.x

Montgomery, 2001, The androgen receptor gene and its influence on the development and progression of prostate cancer., J Pathol, 195, 138, 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y

Hsiao, 1999, The linkage of Kennedy’s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator., J Biol Chem, 274, 20229, 10.1074/jbc.274.29.20229

Gregory, 2001, A mechanism for androgen receptor mediated prostate cancer after androgen deprivation therapy., Cancer Res, 61, 4315

Peehl, 1995, Prostate-specific antigen role and function., Cancer, 75, 2021, 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R

Cohen, 1994, Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease., J Endocrinol, 142, 407, 10.1677/joe.0.1420407

Cramer, 1996, Prostate-specific antigen cleaves parathyroid hormone related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts., J Urol, 156, 526, 10.1016/S0022-5347(01)65919-6

Xue, 2000, Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci., Cancer Res, 60, 839

Ding, Prostate, 58, 23, 10.1002/pros.10316

Edwards, 2001, Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer., BJU Int, 88, 633, 10.1046/j.1464-410X.2001.02350.x

Bubendorf, 1999, Survey of gene amplifications during prostate cancer progression by high throughput fluorescence in situ hybridization on tissue microarrays., Cancer Res, 59, 803

Miyoshi, 2000, Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients., Prostate, 43, 225, 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7

Visakorpi, 1995, In vivo amplification of the androgen receptor gene and progression of human prostate cancer., Nat Genet, 9, 401, 10.1038/ng0495-401

Linja, 2001, Amplification and overexpression of androgen receptor gene in hormone refractory prostate cancer., Cancer Res, 61, 3550

Koivisto, 1999, Androgen receptor gene amplification increases tissue PSA protein expression in hormone refractory prostate carcinoma., J Pathol, 189, 219, 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F

Koivisto, 1997, Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer., Cancer Res, 57, 314

Wallen, 1999, Androgen receptor gene mutations in hormone refractory prostate cancer., J Pathol, 189, 559, 10.1002/(SICI)1096-9896(199912)189:4<559::AID-PATH471>3.0.CO;2-Y

Shi, 2002, Functional analysis of 44 mutant androgen receptors from human prostate cancer., Cancer Res, 62, 1496

Grossmann, 2001, Androgen receptor signaling in androgen refractory prostate cancer., J Natl Cancer Inst, 93, 1687, 10.1093/jnci/93.22.1687

Feldman, 2001, The development of androgen-independent prostate cancer., Nat Rev Cancer, 1, 34, 10.1038/35094009

Palmberg, 2000, Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer., J Urol, 164, 1992, 10.1016/S0022-5347(05)66935-2

Honchel, 1995, Genomic instability in neoplasia., Semin Cell Biol, 6, 45, 10.1016/1043-4682(95)90014-4

Brison, 1993, Gene amplification and tumor progression., Biochim Biophys Acta, 1155, 25

Gao, 1994, High frequency of mutator phenotype in human prostatic adenocarcinoma., Oncogene, 9, 2999

Crundwell, 1999, Genetic instability in incidentally discovered and advanced prostate cancer., BJU Int, 84, 123, 10.1046/j.1464-410x.1999.00152.x

Dahiya, 1997, High frequency of genetic instability of microsatellintes in human prostatic adenocarcinoma., Int J Cancer, 72, 762, 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B

Anzick, 1997, AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer., Science, 277, 965, 10.1126/science.277.5328.965

Clark, 2002, Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones., Genes Chromosomes Cancer, 34, 104, 10.1002/gcc.10039

Zhu, 1999, Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer., Proc Natl Acad Sci USA, 96, 10848, 10.1073/pnas.96.19.10848

McKenna, 1999, Nuclear receptor coregulators: cellular and molecular biology., Endocr Rev, 20, 321

Gnanapragasam, 2001, Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer., Br J Cancer, 85, 1928, 10.1054/bjoc.2001.2179

Louie, 2003, Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex., Proc Natl Acad Sci USA, 100, 2226, 10.1073/pnas.0437824100

Yeh, 1996, Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells., Proc Natl Acad Sci USA, 93, 5517, 10.1073/pnas.93.11.5517

Gregory, 1998, Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes., Cancer Res, 58, 5718

Ngan, 2003, Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer., Oncogene, 22, 734, 10.1038/sj.onc.1206121

Halkidou, 2003, Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development., Oncogene, 22, 2466, 10.1038/sj.onc.1206342

Ishiguro, 2003, 55 kDa Nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor., Int J Cancer, 105, 26, 10.1002/ijc.11021

Fujimoto, 1999, Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate., J Biol Chem, 274, 8316, 10.1074/jbc.274.12.8316

Berrevoets, 1998, Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2)., Mol Endocrinol, 12, 1172, 10.1210/mend.12.8.0153

Yeh, 1998, From estrogen to androgen receptor: a new pathway for sex hormones in prostate., Proc Natl Acad Sci USA, 95, 5527, 10.1073/pnas.95.10.5527

Miyamoto, 1998, Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells., Proc Natl Acad Sci USA, 95, 11083, 10.1073/pnas.95.19.11083

Gregory, 2001, Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen., Cancer Res, 61, 2892

Miyamoto, 2002, A dominant-nega-tive mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth., J Biol Chem, 277, 4609, 10.1074/jbc.M108312200

Chang, 2002, Evaluation of ligand-dependent changes in AR structure using peptide probes., Mol Endocrinol, 16, 647, 10.1210/mend.16.4.0818

Zhou, 2002, Domain interactions between coregulator ARA70 and the androgen receptor (AR)., Mol Endocrinol, 16, 287, 10.1210/mend.16.2.0765

He, 1999, Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain., J Biol Chem, 274, 37219, 10.1074/jbc.274.52.37219

Bevan, 1999, The AF-1 and AF-2 domains of the androgen receptor interact with distinct regions of SRC1., Mol Cell Biol, 19, 8383, 10.1128/MCB.19.12.8383

Yeh, 1998, Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells., Biochem Biophys Res Comm, 248, 361, 10.1006/bbrc.1998.8974

Lu, 1998, Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein., J Biol Chem, 273, 31528, 10.1074/jbc.273.47.31528

Weinberg, 1995, The retinoblastoma protein and cell cycle control., Cell, 81, 323, 10.1016/0092-8674(95)90385-2

Theodorescu, 1997, p53, bcl-2, and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate., J Urol, 158, 131, 10.1097/00005392-199707000-00040

Mack, 1998, Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade., Prostate, 34, 145, 10.1002/(SICI)1097-0045(19980201)34:2<145::AID-PROS10>3.0.CO;2-I

Tricoli, 1996, Alterations in the retinoblastoma gene in human prostate adenocarcinoma., Genes Chromosomes Cancer, 15, 108, 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7

Harbour, 2000, The Rb/E2F pathway: expanding roles and emerging paradigms., Genes Dev, 14, 2393, 10.1101/gad.813200

Yeh, 2000, Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells., Proc Natl Acad Sci USA, 97, 11256, 10.1073/pnas.190353897

Ford, 1994, Risks of cancer in BRCA1 mutation carriers. Breast Cancer Linkage Consortium., Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4

Wilkens, 1999, No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer., Prostate, 39, 280, 10.1002/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F

Sinclair, 2000, BRCA1 and BRCA2 have a limited role in familial prostate cancer., Cancer Res, 60, 1371

Vazina, 2000, The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel., Br J Cancer, 83, 463, 10.1054/bjoc.2000.1249

Rosen, 2001, BRCA1 and prostate cancer., Cancer Invest, 19, 396, 10.1081/CNV-100103134

Shin, 2003, BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription., Proc Natl Acad Sci USA, 100, 7201, 10.1073/pnas.1132020100

Simpson, 2001, PTEN: life as a tumor suppressor., Exp Cell Res, 264, 29, 10.1006/excr.2000.5130

McMenamin, 1999, Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage., Cancer Res, 59, 4291

Djakiew, 2000, Dysregulated expression of growth factors and their receptors in the development of prostate cancer., Prostate, 42, 150, 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H

Cronauer, 1997, Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate., Prostate, 31, 223, 10.1002/(SICI)1097-0045(19970601)31:4<223::AID-PROS3>3.0.CO;2-L

Culig, 1994, Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor., Cancer Res, 54, 5474

Nakamoto, 1992, Basic fibroblast growth factor in human prostate cancer cells., Cancer Res, 52, 571

Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies., Crit Rev Oncol Hematol, 19, 183, 10.1016/1040-8428(94)00144-I

Menard, 2000, Role of HER2 gene overexpression in breast carcinoma., J Cell Physiol, 182, 150, 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E

Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene., Science, 235, 177, 10.1126/science.3798106

Klotz, 1990, Molecular analysis of neu, sis, c-myc, fos and p53 oncogenes in benign prostatic hypertrophy and prostatic carcinoma, J Urol, 143, 401A

McCann, 1990, c-erbB-2 Oncoprotein expression in primary human tumors., Cancer, 65, 88, 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z

Morote, 1999, Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer., Int J Cancer, 84, 421, 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9

Kuhn, 1993, Expression of the c-erbB-2 (Her2/neu) oncoprotein in human prostatic carcinoma., J Urol, 150, 1427, 10.1016/S0022-5347(17)35799-3

Sadasivan, 1993, Overexpression of Her2/neu may be an indicator of poor prognosis in prostate cancer., J Urol, 150, 126, 10.1016/S0022-5347(17)35413-7

Signoretti, 2000, Her2-neu expression and progression toward androgen independence in human prostate cancer., J Natl Cancer Inst, 92, 1918, 10.1093/jnci/92.23.1918

Myers, J Natl Cancer Inst, 86, 1140, 10.1093/jnci/86.15.1140

Craft, 1999, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by HER-2/neu tyrosine kinase., Nat Med, 5, 280, 10.1038/6495

Yeh, 1999, From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells., Proc Natl Acad Sci USA, 96, 5458, 10.1073/pnas.96.10.5458

Yart, 2001, A critical role for phosphoinositide 3 kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor., J Biol Chem, 276, 8856, 10.1074/jbc.M006966200

Downward, 1998, Ras signalling and apoptosis., Curr Opin Genet Dev, 8, 49, 10.1016/S0959-437X(98)80061-0

Campbell, 1998, Increasing complexity or Ras signaling., Oncogene, 17, 1395, 10.1038/sj.onc.1202174

Zimmerman, 1999, Phosphorylation and regulation of Raf by Akt (protein kinase B)., Science, 286, 1741, 10.1126/science.286.5445.1741

Rommel, 1999, Differentiation stage-specific inhibition of the Raf-Mek-Erk pathway by Akt., Science, 286, 1738, 10.1126/science.286.5445.1738

Tremblay, 1999, Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1., Mol Cell, 3, 513, 10.1016/S1097-2765(00)80479-7

Hammer, 1999, Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress., Mol Cell, 3, 521, 10.1016/S1097-2765(00)80480-3

Rowan, 2000, Phosphorylation of steroid receptor coactivator-1: identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway., J Biol Chem, 275, 4475, 10.1074/jbc.275.6.4475

Rowan, 2000, 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein., Mol Cell Biol, 20, 8720, 10.1128/MCB.20.23.8720-8730.2000

Lopez, 2001, Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity., J Biol Chem, 276, 22177, 10.1074/jbc.M010718200

Font de Mora, 2000, AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor., Mol Cell Biol, 20, 5041, 10.1128/MCB.20.14.5041-5047.2000

Connolly, 1990, Production of epidermal growth factor and transforming growth factor α by the androgen responsive LNCaP human prostate cancer cell line., Prostate, 16, 209, 10.1002/pros.2990160304

Grasso, 1997, ErbB kinases and NDF signaling in human prostate cancer cells., Oncogene, 15, 2705, 10.1038/sj.onc.1201447

Gupta, 1999, Modulation of androgen receptor (AR)-mediated transcriptional activity by EGF in the developing mouse reproductive tract primary cells., Mol Cell Endocrinol, 152, 169, 10.1016/S0303-7207(99)00048-9

Reinikainen, 1996, Effects of mitogens on androgen receptor-mediated transactivation., Endocrinology, 137, 4351, 10.1210/endo.137.10.8828495

Langeler, 1993, Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP., Prostate, 23, 213, 10.1002/pros.2990230304

Henttu, 1993, Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP., Cancer Res, 53, 1051

Wen, 2000, Her2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway., Cancer Res, 60, 6841

Graff, 2000, Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27KIP1 expression., J Biol Chem, 275, 24500, 10.1074/jbc.M003145200

Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN., Cell, 95, 29, 10.1016/S0092-8674(00)81780-8

Di Cristofano, 2000, The multiple roles of PTEN in tumor suppression., Cell, 100, 387, 10.1016/S0092-8674(00)80674-1

Cairns, 1997, Frequent inactivation of PTEN/MMAC1 in primary prostate cancer., Cancer Res, 57, 4997

Li, 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer., Science, 275, 1943, 10.1126/science.275.5308.1943

Di Cristofano, 1998, Pten is essential for embryonic development and tumor suppression., Nat Genet, 19, 348, 10.1038/1235

Ramaswamy, 1999, Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway., Proc Natl Acad Sci USA, 96, 2110, 10.1073/pnas.96.5.2110

Davies, 1999, Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN., Cancer Res, 59, 2551

Li, 2001, Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells., J Biol Chem, 276, 20444, 10.1074/jbc.M010226200

Olayioye, 2000, The ErbB signaling network: receptor heterodimerization in development and cancer., EMBO J, 19, 3159, 10.1093/emboj/19.13.3159

Leung, 1997, A potential autocrine loop between heregulin α and erbB3 receptor in human prostatic adenocarcinoma., Br J Urol, 79, 212, 10.1046/j.1464-410X.1997.30412.x

Okano, 2000, Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation., J Biol Chem, 275, 30934, 10.1074/jbc.M004112200

Lee, 1999, Transforming growth factor β in benign and malignant prostate., Prostate, 39, 285, 10.1002/(SICI)1097-0045(19990601)39:4<285::AID-PROS9>3.0.CO;2-7

Wong, 2000, Structural changes and alteration in expression of TGF-β1 and its receptors in prostatic intraepithelial neoplasia (PIN) in the ventral prostate of Noble rats., Prostate, 45, 289, 10.1002/1097-0045(20001201)45:4<289::AID-PROS2>3.0.CO;2-O

Nemeth, 1997, Prostatic ductal system in rats: tissue specific expression and regional variation in stromal distribution of transforming growth factor β1., Prostate, 33, 64, 10.1002/(SICI)1097-0045(19970915)33:1<64::AID-PROS11>3.0.CO;2-J

Martikainen, 1990, Effect of transforming growth factor β1 on proliferation and death of rat prostatic cells., Endocrinology, 127, 2963, 10.1210/endo-127-6-2963

Sutkowski, 1992, Interaction of epidermal growth factor and transforming growth factor β in human prostatic epithelial cells in culture., Prostate, 21, 133, 10.1002/pros.2990210206

Kyprianou, 1989, Expression of transforming growth factor β in the rat ventral prostate during castration-induced programmed cell death., Mol Endocrinol, 3, 1515, 10.1210/mend-3-10-1515

Wilding, 1991, Response of prostate cancer cells to peptide growth factors: transforming growth factor β., Cancer Surv, 11, 147

Lamm, 1998, A proliferative effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1., Endocrinology, 139, 787, 10.1210/endo.139.2.5907

Guo, 1998, Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells., Cell Growth Differ, 9, 185

Barrack, 1997, TGF β in prostate cancer: a growth inhibitor that can enhance tumorigenicity., Prostate, 31, 61, 10.1002/(SICI)1097-0045(19970401)31:1<61::AID-PROS10>3.0.CO;2-M

Stravodimos, 2000, Immunohistochemical expression of TGF β1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters., Anticancer Res, 20, 3823

Hayes, 2001, Smad 3 represses androgen receptor-mediated transcription., Cancer Res, 61, 2112

Kang, 2001, From transforming growth factor β signaling to androgen action: identification of Smad 3 as an androgen receptor coregulator in prostate cancer cells., Proc Natl Acad Sci USA, 98, 3018, 10.1073/pnas.061305498

Kang, 2002, Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4., J Biol Chem, 277, 43749, 10.1074/jbc.M205603200

Massague, 2000, Controlling TGF-β signaling., Genes Dev, 14, 627, 10.1101/gad.14.6.627

Avraham, 2000, RAFTK/Pyk2-mediated cellular signalling., Cell Signal, 12, 123, 10.1016/S0898-6568(99)00076-5

Koziak, 2001, RAFTK/Pyk2 involvement in platelet activation is mediated by phosphoinositide 3-kinase., Br J Haematol, 114, 134, 10.1046/j.1365-2141.2001.02894.x

Liu, 1997, Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi’s sarcoma cells., J Clin Invest, 99, 1798, 10.1172/JCI119344

Schlaepfer, 1998, Integrin signalling and tyrosine phosphorylation: just the FAKs?, Trends Cell Biol, 8, 151, 10.1016/S0962-8924(97)01172-0

Dikic, 1996, A role for Pyk2 and Src in linking G-protein coupled receptors with MAP kinase activation., Nature, 383, 547, 10.1038/383547a0

Ishino, 2000, Phosphorylation of Hic-5 at tyrosine 60 by CAK β and Fyn., FEBS Lett, 474, 179, 10.1016/S0014-5793(00)01597-0

Shibanuma, 1994, Characterization of the TGFβ1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence., J Biol Chem, 269, 26767, 10.1016/S0021-9258(18)47085-8

Stanzione, 2001, Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression., Lab Invest, 81, 51, 10.1038/labinvest.3780211

Wang, 2002, Suppression of androgen receptor transactivation by PYK2 via interaction and phosphorylation of the ARA55 coregulator., J Biol Chem, 277, 15426, 10.1074/jbc.M111218200

Xiong, 1997, Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase., J Cell Biol, 139, 529, 10.1083/jcb.139.2.529

Chauhan, 1999, RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells., Oncogene, 18, 6733, 10.1038/sj.onc.1203082

Ueda, 2000, Suppression of PYK2 kinase and cellular activities by FIP2000., J Cell Biol, 149, 423, 10.1083/jcb.149.2.423

Picascia, 2002, Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells., Mol Cell Endocrinol, 186, 81, 10.1016/S0303-7207(01)00667-0

Nishiya, 2001, Hic-5 reduced cell spreading on fibronectin: competitive effects between paxillin and Hic-5 through interaction with focal adhesion kinase., Mol Cell Biol, 21, 5332, 10.1128/MCB.21.16.5332-5345.2001

Shibanuma, 1997, Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts., Mol Cell Biol, 17, 1224, 10.1128/MCB.17.3.1224

Keller, 1996, Molecular and cellular biology of interleukin-6 and its receptor, Front Biosci, 1, d340, 10.2741/A136

Hoosein, 1995, Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer., Urol Oncol, 1, 246, 10.1016/1078-1439(96)00012-9

Adler, 1999, Elevated levels of circulating interleukin-6 and transforming growth factor β1 in patients with metastatic prostatic carcinoma., J Urol, 161, 182, 10.1016/S0022-5347(01)62092-5

Twillie, 1995, Interleukin-6: a candidate mediator of human prostate cancer morbidity., Urology, 45, 542, 10.1016/S0090-4295(99)80034-X

Drachenberg, 1999, Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer., Prostate, 41, 127, 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H

Ward, 1994, High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp130., J Biol Chem, 269, 23286, 10.1016/S0021-9258(17)31651-4

Murakami, 1993, IL-6 induced homodimerization of gp130 and associated activation of a tyrosine kinase., Science, 260, 1808, 10.1126/science.8511589

Stahl, 1994, Association and activation of JAK-tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components., Science, 163, 92, 10.1126/science.8272873

Akira, 1997, IL-6 regulated transcription factors., Int J Biochem Cell Biol, 29, 1401, 10.1016/S1357-2725(97)00063-0

Wen, 1995, Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation., Cell, 82, 241, 10.1016/0092-8674(95)90311-9

Darnell, 1994, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins., Science, 264, 1415, 10.1126/science.8197455

Cutler, 1993, Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hematopoietic cells., J Biol Chem, 268, 21463, 10.1016/S0021-9258(20)80558-4

Qiu, 1998, Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells., Nature, 393, 83, 10.1038/30012

Chen, 1999, Elevation of cyclic adenosine 3′, 5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells., Cancer Res, 59, 213

Turkson, 1999, Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in STAT3 transcriptional activity induced by the Src oncoprotein., Mol Cell Biol, 19, 7519, 10.1128/MCB.19.11.7519

Gollob, 1999, The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation., J Immunol, 162, 4472, 10.4049/jimmunol.162.8.4472

Chung, 1997, STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation., Mol Cell Biol, 17, 6508, 10.1128/MCB.17.11.6508

Lim, 2001, Regulation of STAT3 activation by MEK kinase 1., J Biol Chem, 276, 21004, 10.1074/jbc.M007592200

Qiu, 1998, Etk/Bmx, a tyrosine kinase with a pleckstrin homology domain is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells., Proc Natl Acad Sci USA, 95, 3644, 10.1073/pnas.95.7.3644

Chung, 2000, Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines., Prostate, 42, 1, 10.1002/(SICI)1097-0045(20000101)42:1<1::AID-PROS1>3.0.CO;2-Y

Spiotto, 2000, STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP., Prostate, 42, 88, 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P

Degeorges, 1996, Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6., Int J Cancer, 68, 207, 10.1002/(SICI)1097-0215(19961009)68:2<207::AID-IJC12>3.0.CO;2-7

Spiotto, 2000, STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells., Prostate, 42, 186, 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E

Yang, 2003, Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells., Biochem Biophys Res Comm, 305, 462, 10.1016/S0006-291X(03)00792-7

Lin, 2001, Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor., Proc Natl Acad Sci USA, 98, 7200, 10.1073/pnas.121173298

Lin, J Biol Chem, 278, 50902, 10.1074/jbc.M300676200

Yang, 2003, APPL suppresses androgen receptor transactivation via potentiating Akt activity., J Biol Chem, 278, 16820, 10.1074/jbc.M213163200

Poulin, 1988, Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line., Breast Cancer Res Treat, 12, 213, 10.1007/BF01805942

Marshall, 1995, Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation., Cell, 80, 179, 10.1016/0092-8674(95)90401-8

Okamoto, 1997, Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro., Cancer Res, 57, 141

Lou, 2000, Interleukin-6 induces prostate cancer cell growth accompanied by activation of STAT3 signaling pathway., Prostate, 42, 239, 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G

Chen, 2000, Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells., Cancer Res, 60, 2132

Hobisch, 1998, Interleukin-6 regulates prostate-specific expression in prostate carcinoma cells by activation of the androgen receptor., Cancer Res, 58, 4640

Matsuda, 2001, Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells., Biochem Biophys Res Comm, 283, 179, 10.1006/bbrc.2001.4758

Ueda, 2002, Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways., J Biol Chem, 277, 7076, 10.1074/jbc.M108255200

Ueda, 2002, Ligand-independent activation of the androgen receptor by IL-6 and the role of SRC-1 in prostate cancer cells., J Biol Chem, 277, 38087, 10.1074/jbc.M203313200

Debes, 2002, p300 mediates androgen-independent transactivation of the androgen receptor by IL6., Cancer Res, 62, 5632

Hobisch, 2000, Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant, and malignant prostate tissue., J Pathol, 191, 239, 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X

Chung, 1999, Characterization of the role of IL-6 in the progression of prostate cancer., Prostate, 38, 199, 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H

Kovalovich, 2001, Interleukin-6 protects against Fas-mediated death by establishing a critical level of antiapoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL., J Biol Chem, 276, 26605, 10.1074/jbc.M100740200

Turkson, 2000, STAT proteins: novel molecular targets for cancer drug discovery., Oncogene, 19, 6613, 10.1038/sj.onc.1204086

Grandis, 2000, Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo., Proc Natl Acad Sci USA, 97, 4227, 10.1073/pnas.97.8.4227

Baserga, 1997, The IGF-I receptor in cell growth, transformation and apoptosis, Biochim Biophys Acta, 1332, F105

Djavan, 2001, Insulin-like growth factors and prostate cancer., World J Urol, 19, 225, 10.1007/s003450100220

Craparo, 1995, Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor., J Biol Chem, 270, 15639, 10.1074/jbc.270.26.15639

Myers Jr, 1994, Insulin receptor substrate-1 mediates phosphatidylinositol 3′kinase and p70S6K signaling during insulin, insulin-like growth factor-1 and interleukin-4 stimulation., J Biol Chem, 269, 28783, 10.1016/S0021-9258(19)61974-5

Khandwala, 2000, The effects of insulin-like growth factors on tumorigenesis and neoplastic growth., Endocr Rev, 21, 215, 10.1210/edrv.21.3.0399

Pollak, 2001, Insulin-like growth factors and prostate cancer., Epidemiol Rev, 23, 59, 10.1093/oxfordjournals.epirev.a000796

Tennant, 1996, Insulin-like growth factor binding protein-2 and -3 expression in benign human prostate epithelium, prostatic intraepithelial neoplasia, and adenocarcinoma., J Clin Endocrinol Metab, 81, 411

Tennant, 1996, Insulin-like growth factor binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization., J Clin Endocrinol Metab, 81, 3783

Miyake, 2000, Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′ kinase pathway., Endocrinology, 141, 2257, 10.1210/endo.141.6.7520

DiGiovanni, 2000, Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice., Proc Natl Acad Sci USA, 97, 3455, 10.1073/pnas.97.7.3455

Culig, 1997, Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells., Prostate, 32, 106, 10.1002/(SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K

Takahashi, 1995, Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men., Cancer Res, 55, 1621

Marcelli, 2000, Androgen receptor mutations in prostate cancer., Cancer Res, 60, 944

Suzuki, 1993, Androgen receptor gene mutations in human prostate cancer., J Steroid Biochem Mol Biol, 46, 759, 10.1016/0960-0760(93)90316-O

Tilley, 1996, Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence., Clin Cancer Res, 2, 277

Hara, 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome., Cancer Res, 63, 149

Buchanan, 2001, Collocation of androgen receptor gene mutations in prostate cancer., Clin Cancer Res, 7, 1273

Taplin, 2003, Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663., J Clin Oncol, 21, 2673, 10.1200/JCO.2003.11.102

Gaddipati, 1994, Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer., Cancer Res, 54, 2861

Taplin, 1999, Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist., Cancer Res, 59, 2511

Taplin, 1995, Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer., N Engl J Med, 332, 1393, 10.1056/NEJM199505253322101

Veldscholte, 1990, A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens., Biochem Biophys Res Commun, 173, 534, 10.1016/S0006-291X(05)80067-1

Wilding, 1989, Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens., Prostate, 14, 103, 10.1002/pros.2990140204

Tan, 1997, Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells., Mol Endocrinol, 11, 450, 10.1210/mend.11.4.9906

Culig, 1993, Mutant androgen receptor detected in an advanced stage prostatic carcinoma is activated by adrenal androgens and progesterone., Mol Endocrinol, 7, 1541

Fenton, 1997, Functional characterization of mutant androgen receptors from androgen-independent prostate cancer., Clin Cancer Res, 3, 1383

Mononen, 2000, Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone binding domain of the androgen receptor., Cancer Res, 60, 6479

Miyamoto, 1998, Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate DU145 cells., Proc Natl Acad Sci USA, 95, 7379, 10.1073/pnas.95.13.7379

Ting, 2002, Supervillin associates with androgen receptor and modulates its transcriptional activity., Proc Natl Acad Sci USA, 99, 661, 10.1073/pnas.022469899

Voeller, 1998, β Catenin mutations in human prostate cancer., Cancer Res, 58, 2520

Truica, 2000, β-Catenin affects androgen receptor transcriptional activity and ligand specificity., Cancer Res, 60, 4709

Han, 2001, Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer., J Biol Chem, 276, 11204, 10.1074/jbc.M008207200

Agoulnik, 2000, A subset of coactivators broadens ligand specificity for transactivation by the androgen receptor, Keystone Symposia

Thin, 2002, Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of the 17β estradiol-induced androgen receptor transactivation., J Biol Chem, 277, 36499, 10.1074/jbc.M202824200

Rahman, 2003, Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells., Proc Natl Acad Sci USA, 100, 5124, 10.1073/pnas.0530097100

Ganjam, 1976, Steroids in fluids and sperm entering and leaving the bovine epididymis, epididymal tissue, and accessory sex gland secretions., Endocrinology, 99, 1618, 10.1210/endo-99-6-1618

Hiramatsu, 1997, Aromatase in hyperplasia and carcinoma of the human prostate., Prostate, 31, 118, 10.1002/(SICI)1097-0045(19970501)31:2<118::AID-PROS7>3.0.CO;2-J

Negri-Cesi, 1998, Presence of 5α-reductase isozymes and aromatase in human prostate cancer cells and in benign hyperplastic tissue., Prostate, 34, 283, 10.1002/(SICI)1097-0045(19980301)34:4<283::AID-PROS6>3.0.CO;2-I

Mikkola, 1998, Parenteral polyoestradiol phosphate vs. orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national prospective prostatic cancer study., Br J Urol, 82, 63, 10.1046/j.1464-410x.1998.00688.x

Santen, 1992, Endocrine treatment of prostate cancer., J Clin Endocrinol Metab, 75, 685

Scher, 1996, Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer., Urology, 47, 61, 10.1016/S0090-4295(96)80011-2

Ziada, 2000, 324

Sartor, 1994, Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of “hormone refractory” prostate cancer., J Natl Cancer Inst, 86, 222, 10.1093/jnci/86.3.222

Harris, 2002, Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen-independent prostate cancer., J Urol, 168, 542, 10.1016/S0022-5347(05)64675-7

Small, 1997, Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma., Cancer, 80, 1755, 10.1002/(SICI)1097-0142(19971101)80:9<1755::AID-CNCR9>3.0.CO;2-D

Shang, 2002, Formation of the androgen receptor transcription complex., Mol Cell, 9, 601, 10.1016/S1097-2765(02)00471-9

Song, Mol Endocrinol, 18, 70, 10.1210/me.2003-0189

Liao, 2003, Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT., J Biol Chem, 278, 5052, 10.1074/jbc.M206374200

Agoulnik, 2003, Repressors of androgen and progesterone receptor action., J Biol Chem, 278, 31136, 10.1074/jbc.M305153200

Lavinsky, 1998, Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes., Proc Natl Acad Sci USA, 95, 2920, 10.1073/pnas.95.6.2920

Yeh, 1997, Hydroxyflutamide may not always be a pure antiandrogen., Lancet, 349, 852, 10.1016/S0140-6736(05)61756-4

Miyamoto, 2004, Molecular basis for the antiandrogen withdrawal syndrome., J Cell Biochem, 91, 3, 10.1002/jcb.10757

Debes, Cancer Res, 63, 7638

Nishimura, 2003, Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator., Cancer Res, 63, 4888

Rahman, 2003, Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells., J Biol Chem, 278, 19619, 10.1074/jbc.M210941200

Comuzzi, 2003, The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function., Am J Path, 162, 233, 10.1016/S0002-9440(10)63814-X

Lee, 2002, Activation of MAP kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor negative prostate cancer cells., Cancer Res, 62, 6039

Heinlein, 2002, The roles of androgen receptors and androgen binding proteins in nongenomic androgen action., Mol Endocrinol, 16, 2181, 10.1210/me.2002-0070

Falkenstein, 2000, Multiple actions of steroid hormones: a focus on rapid, nongenomic effects., Pharmacol Rev, 52, 513

Revelli, 1998, Nongenomic actions of steroid hormones in reproductive tissues., Endocr Rev, 19, 3

Gerdes, 1998, Cloning and tissue expression of two putative steroid membrane receptors., Biol Chem, 379, 907

Bernauer, 2001, The human membrane progesterone receptor gene: genomic structure and promoter analysis., DNA Seq, 12, 13, 10.3109/10425170109042047

Levin, 2002, Cellular functions of plasma membrane estrogen receptors., Steroids, 67, 471, 10.1016/S0039-128X(01)00179-9

Watson, 2002, The dynamic and elusive membrane estrogen receptor-α., Steroids, 67, 429, 10.1016/S0039-128X(01)00172-6

Luzardo, 2000, Photoaffinity labeling identification of a specific binding protein for the anabolic steroids stanozolol and danazol: an oligomeric protein regulated by age, pituitary hormones, and ethinyl estradiol., Endocrinology, 141, 337, 10.1210/endo.141.9.7667

Migliaccio, 2000, Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation., EMBO J, 19, 5406, 10.1093/emboj/19.20.5406

Kousteni, 2001, Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity., Cell, 104, 719

Bakin, 2003, Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells., Cancer Res, 63, 1981

Bakin, 2003, Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells., Cancer Res, 63, 1975

Siiteri, 1982, The serum transport of steroid hormones., Recent Prog Horm Res, 38, 457

Mendel, 1989, The free hormone hypothesis: a physiologically based mathematical model., Endocr Rev, 10, 232, 10.1210/edrv-10-3-232

Nakhla, 1999, Sex hormone-binding globulin receptor signal transduction proceeds via a G protein., Steroids, 64, 213, 10.1016/S0039-128X(98)00084-1

Rosner, 1999, Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate., Steroids, 64, 100, 10.1016/S0039-128X(98)00108-1

Porto, 1995, Receptors for androgen-binding proteins: internalization and intracellular signalling., J Steroid Biochem Mol Biol, 53, 561, 10.1016/0960-0760(95)00111-C

Fortunati, 1999, Sex hormone-binding globulin: not only a transport protein. What news around the corner?, J Endocrinol Invest, 22, 223, 10.1007/BF03343547

Nakhla, 1997, Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone binding globulin., J Biol Chem, 272, 6838, 10.1074/jbc.272.11.6838

Ding, 1998, Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway., Endocrinology, 139, 213, 10.1210/endo.139.1.5681

Ikonen, 1994, Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation., Endocrinology, 135, 1359, 10.1210/endo.135.4.7925097

Ko, 2002, Identification and characterization of a tissue-specific coactivator, GT198, that interacts with the DNA binding domains of nuclear receptors., Mol Cell Biol, 22, 357, 10.1128/MCB.22.1.357-369.2002

Gao, 2001, Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells., Cancer Res, 61, 5038

Joly-Pharaboz, 1995, Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP., J Steroid Biochem Mol Biol, 55, 67, 10.1016/0960-0760(95)00155-S

Lin, 2001, Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression., Clin Cancer Res, 7, 1773

Miyamoto, 2003, 3 β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity., Proc Natl Acad Sci USA [Erratum (2003) 100:6891], 100, 4440, 10.1073/pnas.0831001100

Le, 2003, Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells., J Biol Chem, 278, 21136, 10.1074/jbc.M300588200

Wang, 2002, 197

Zhang, 2002, Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells., Proc Natl Acad Sci USA, 99, 7408, 10.1073/pnas.102014399

Mitchell, 1999, Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells., Cancer Res, 59, 5892

Narayanan, 2003, Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets., Int J Cancer, 104, 204, 10.1002/ijc.10932

Singh, 2002, Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor binding protein-3 levels., Cancer Res, 62, 3062

Nickerson, 1999, Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins., J Endocrinol, 160, 223, 10.1677/joe.0.1600223

Crocitto, 1997, Identification of two germline point mutations in the 5′UTR of the androgen receptor gene in men with prostate cancer., J Urol, 158, 1599, 10.1016/S0022-5347(01)64287-3

Schoenberg, 1994, Microsatellite mutation (CAG24-18)in the androgen receptor gene in human prostate cancer., Biochem Biophys Res Commun, 198, 74, 10.1006/bbrc.1994.1011

Haapala, 2001, Androgen receptor alterations in prostate cancer relapsed during combined androgen blockade by orchiectomy and bicalutamide., Lab Invest, 81, 1647, 10.1038/labinvest.3780378

Gottlieb, 2001, Variable expressivity and mutation databases: the androgen receptor gene mutations database., Hum Mutat, 17, 382, 10.1002/humu.1113

Nazareth, 1999, A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1)., Mol Endocrinol, 13, 2065, 10.1210/mend.13.12.0382

Peterziel, 1995, Mutant androgen receptors in prostatic tumors distinguish between amino-acid sequence requirements for transactivation and ligand binding., Int J Cancer, 63, 544, 10.1002/ijc.2910630415

Kleinerman, 1996, Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer., J Urol, 155, 624

Elo, 1995, Mutant human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol., J Clin Endocrinol Metab, 80, 3494, 10.1210/jcem.80.12.8530589

Newmark, 1992, Androgen receptor gene mutations in human prostate cancer., Proc Natl Acad Sci USA, 89, 6319, 10.1073/pnas.89.14.6319